What does tempus ai do. Tempus has 37 competitors.

What does tempus ai do olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to Jan 17, 2025 · The average Tempus AI salary ranges from approximately $46,863 per year for Clinical Data Analyst to $168,000 per year for Process Engineer. Tempus AI’s strategic moves and groundbreaking technological applications mark it as a key player in the future of precision medicine, blending AI and data analytics to reshape healthcare delivery. 06. The average Tempus AI salary ranges from approximately $36,000 per year for Laboratory Assistant to $147,000 per year for Staff Scientist. Register now . Jun 3, 2024 · What advice do you have for other health systems looking to improve their precision medicine programs? Karen Huelsman: My advice is to start by understanding AI platforms like Tempus Next. Full-year 2024 revenue What does Tempus AI do? Tempus AI is a health-technology company founded in 2015. SoftBank invested $200 million into Tempus AI earlier this year and announced a joint venture to bring Tempus’ technology to Japan. At the IPO price, the company was valued at Jan 8, 2025 · CHICAGO--(BUSINESS WIRE)--Jan. Feb 13, 2025 · In light of the artificial intelligence (AI) stock's strong performance so far this year, prospective investors may fear there's not much share price growth potential left for Tempus, an innovator Explore Tempus AI's impact on precision medicine, from genomic sequencing to AI diagnostics. This is the first FDA … Continued Jan 31, 2025 · Tempus AI’s Q4 Earnings Report Has Been Strong. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Jan 14, 2025 · Tempus AI offers Tempus One, a generative AI assistant that leverages large language models to query unstructured data for clinical care and research. Valued at $8. Ark Invest made significant buys of Tempus AI shares, adding 719 shares to ARK Genomic Revolution ETF ARKG and 9,100 shares to ARK Innovation ETF ARKK. 78%. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. Founded in 2015, Tempus AI, Inc. 50. It focuses on building platforms for oncology Sep 25, 2024 · Not to put too fine a point on it, but it’s difficult to not get overly cynical about the business’ short-term AI prospects when Tempus was renamed from Tempus Labs to Tempus AI only in 2023. The AI-enabled Tempus One technology will leverage advancements in generative AI to provide researchers the tools they need to seamlessly analyze Tempus’ de-identified, multimodal data library to glean insights Jan 23, 2025 · Tempus AI released its preliminary full-year 2024 results. 405 of this chapter) or Rule 12b-2 of the S Feb 2, 2024 · Tempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. 60 price target. 00. Tony focuses on Tempus One Internal and Agent Builder, two in-house products designed for seamless generative AI * xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE Work wellbeing score is 67 out of 100. 8 out of 5 stars. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024 . Along those Jan 27, 2025 · Tempus AI began trading publicly on June 14, 2024. 5% upside with consensus rating of Buy and $59. Feb 5, 2025 · We recently published a list of Top 10 AI Stocks Trending On Wall Street. Source Feb 24, 2025 · Tempus AI reports fourth-quarter revenue of $200. What does Tempus AI do? Tempus AI is a health-technology company founded in 2015. Feb 20, 2025 · How much does Tempus AI in Chicago pay? The average Tempus AI salary ranges from approximately $47,834 per year for Junior Data Analyst to $166,000 per year for Senior Data Scientist. Public Company. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care, supporting access to the most up-to-date, guideline-directed treatments. 13, 2025-- Tempus AI, Inc. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform Feb 24, 2025 · How long does it take to get hired at Tempus AI? The hiring process at Tempus AI takes an average of 26. uses AI to assist doctors and institutions in fighting cancer and other diseases. Nothing difficult nor challenging about the work and I was compensated properly while being happy with the benefits. Tempus Next is designed to accelerate the … Continued Tempus uses artificial intelligence to help healthcare professionals better diagnose and treat cancer and other diseases. Today, researchers have the potential to learn more from each genetic test without collecting additional samples or adding more work for an ordering … Continued Mar 3, 2025 · What does Tempus AI do? Tempus AI is a health-technology company founded in 2015. Mar 3, 2025 · What does Tempus AI do? Tempus AI is a health-technology company founded in 2015. The Evolution of Generative AI What does Tempus AI do? Tempus AI is a health technology company founded in 2015. Regarding the latter application, Tempus can help predict what drugs a patient may best respond to based on a simple saliva swab – an area of research known as pharmacogenomics. 68 million, missing estimates of $203. Feb 1, 2023 · Genetic testing has been a breakthrough in clinical research and patient profiling, allowing providers to pinpoint the precise factors in a person’s genome that may affect their health or response to treatments. This data can be used to develop new diagnostic tools, therapies, and treatment protocols. Oct 14, 2024 · In a groundbreaking episode of Tempus’s engineering series, Tony Massery, Director of Engineering for Generative AI and Machine Learning, provides an insightful walkthrough of the company’s innovative generative AI tools. Genialis utilizzerà il dataset multimodale di Tempus per convalidare il loro modello fondazionale di intelligenza artificiale, il Genialis™ Supermodel, sviluppato utilizzando circa 1 milione di campioni di sequenziamento RNA. The multi CHICAGO--(BUSINESS WIRE)--Dec. Dec 18, 2024 · Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. MX) stock quote, history, news and other vital information to help you with your stock trading and investing. olivia is an AI Oct 31, 2024 · Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago’s premier integrated academic health system, today announced a collaboration that aims to explore the application of artificial intelligence in clinical care and research. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF). has announced they will report their previous quarter earnings after the close of the market on May 26, 2025. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. The company has built the world’s largest library of clinical and genomic data which will give physicians better insights and ultimately lead to better diagnosis and outcomes. 27%). 2% Mar 8, 2023 · Pathos AI, a spinout of Tempus labs has hired several bioinformatics focused PhD graduates as well as some director level hires from pharma to do this in house. Feb 25, 2025 · Tempus AI (TEM) is transforming healthcare through AI-driven precision medicine, with strong financials, strategic partnerships, and cutting-edge technology in genomics and oncology. In these examples, the beauty is in the future. In all honesty, my typical day was basic Receiving/Inventory Control. Apply to Customer Service Representative, Ai Content Writer, Software Trainer and more! Jan 21, 2025 · Reviews from Tempus AI employees about Tempus AI culture, salaries, benefits, work-life balance, management, job security, and more. 2 days ago · What Does Tempus AI Do? Tempus AI is a cutting-edge artificial intelligence (AI) platform that has revolutionized the way businesses approach time management, scheduling, and workflow optimization. By leveraging clinical and molecular data, we offer comprehensive genomic profiling services, including hereditary testing, minimal residual disease and monitoring, and therapy selection, transforming the way cancer is diagnosed and treated. 1B. 41% and missed on the other by 6. 12M in revenues. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. [relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Tempus AI, Inc. Tempus AI is supposed to IPO in the coming weeks for $6-7 Billion (about 1/3 the market cap of Quest). It provides testing, clinical trial matching, and research data to healthcare providers, researchers, and patients. 2. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against other AI news investors Feb 18, 2025 · Tempus AI (NASDAQ:TEM) is a technology company that integrates genomic and clinical information into its AI platform to offer next-generation products. m. TEM Articles Nancy Pelosi's Tempus AI Up Big Again Today. 21, 2025-- Tempus AI, Inc. By harnessing the power of AI, Tempus is able to analyze vast amounts of data to provide personalized treatment options for patients. At Tempus, we are changing the way precision oncology care is delivered. The platform integrates genomic sequencing, clinical data analysis, and advanced machine learning algorithms to provide comprehensive insights for healthcare providers, life sciences companies, and patients. The company will hold the third quarter 2024 earnings conference call at 4:30 p. 1 million increase in annual gross profit—33. Dec 22, 2024 · We recently published a list of 10 AI News Investors Shouldn’t Miss. 12 million. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential. It is embedding AI into diagnostics to empower physicians and researchers to make personalized, data-driven decisions. Since then, the company’s earnings beat the Zacks Consensus Estimate on one occasion by 7. Average Tempus AI hourly pay ranges from approximately $15. 6 days ago · In addition, Tempus AI, Inc. Jan 22, 2025 · The broader market is recognizing the transformative role AI plays in healthcare, and Tempus stands at the forefront of this innovation. Through its technology, laboratory tests are now able to be embedded with real-world evidence that deliver real-time, actionable insights to physicians, providing critical information about the right 4 days ago · Explore Tempus AI stock price, quotes, charts and forecasts with Benzinga. xT CDx is a FDA-approved test that … Continued 4 days ago · Tempus AI, Inc is a healthcare technology company. operates as a healthcare technology company. Genomics grew 30%, and data/services segments grew 45%. ? + Based on short-term price targets offered by 10 analysts, the average price target for Tempus AI comes to $59. This means its main clients will be Feb 24, 2025 · Tempus AI Inc. 1 million shares priced at $37 a share. Stay updated on market trends for TEM. Jan 6, 2025 · Generative AI is driving transformative change across industries, and at Tempus, we are leveraging this cutting-edge technology to revolutionize precision medicine. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. You may pay the bill to Tempus, or endorse the check from your insurance company to Tempus by signing the back of the check on the top line of the endorsement area and writing “pay to the order of Tempus Labs” on the second line. Jan 14, 2025 · Tempus is building and deploying a series of AI models on top of its library of real-world, multimodal data that enables both physicians to access the data needed to make the most informed Dec 17, 2024 · Tempus AI, Inc. It’s important to have a dedicated individual who can manage the integration and communication between the AI system and healthcare providers. Tempus AI's stock surged by Apr 16, 2024 · Tempus, a leader in artificial intelligence and precision medicine, is introducing Tempus Next, a care pathway intelligence platform. Jan 13, 2025 · CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. ET. Raised a total funding of $1. Information is provided 'as-is' and solely for informational purposes and is not advice. According The average Tempus AI salary ranges from approximately $54,589 per year for Operations Associate to $78,498 per year for Operations Intern. Chicago, Illinois-based Tempus AI, Inc. 3 days ago · Tempus AI also just released its Q4 2024 earnings and the highlights include: Annual revenue of $693. Apr 20, 2021 · Tempus uses AI to help doctors and institutions to fight cancer and other diseases. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. 's stock (TEM) debuted on the Nasdaq on June 14, after the company's initial public offering of 11. Feb 4, 2025 · Here, Tempus AI (TEM) is a name that Nancy Pelosi recently announced a stake in. Jan 21, 2025 · CHICAGO--(BUSINESS WIRE)--Jan. 7 out of 5 stars. Jan 22, 2025 · Tempus AI’s strategic moves and groundbreaking technological applications mark it as a key player in the future of precision medicine, blending AI and data analytics to reshape healthcare delivery. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. What Does Tempus AI Actually Do? Unveiling the AI Revolution in Healthcare - Learn about Tempus AI's transformative role in healthcare, exploring how it uses AI for genomic sequencing, data Jan 21, 2025 · Tempus AI, Inc. (NASDAQ: TEM), a leader in AI and precision medicine, announced it has received 510(k) clearance from the FDA for its Tempus ECG-AF device. Jun 6, 2024 · Research Acceleration: Tempus AI’s platform facilitates research by providing researchers with access to a vast amount of anonymized patient data. 67. Jan 14, 2025 · Analysts have recently evaluated Tempus AI and provided 12-month price targets. How to Use Tempus AI. 49%), a company applying AI solutions to healthcare, has seen its stock perform exceptionally well this year. It collects clinical and genomic databases from academic medical centers and community-based hospitals. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. 80% YTD. 31 days when considering 202 user submitted interviews across all job titles. In the fourth quarter, they achieved a 35% growth in revenue compared to the same period in the previous year, reaching $200 million. Brandon Fornwalt, Senior Vice President of Cardiology at Tempus, Dr. It is embedding AI into diagnostics to empower physicians and researchers to make personalized data-driven decisions. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA Tempus was named one of the best large places to work in Chicago, San Francisco, New York, Boston, and Atlanta as well as one of the best places to work in Boston and Atlanta. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Tempus will send a bill to you for the amount owed once we are notified by your insurance company. (TEM) report earnings? + Tempus AI, Inc. S. 07% upside, outperforming the average forecast for the healthcare stocks sector (23. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. The platform now features four key innovations: Patient Query for improved clinical trial matching, Patient Timeline for comprehensive patient journey visualization, Prior Authorization to streamline administrative processes, and Data Jan 23, 2025 · What does Tempus AI do? Tempus AI is a health technology company founded in 2015. ECG-AF is one of … Continued Jan 22, 2025 · Tempus AI’s strategic moves and groundbreaking technological applications mark it as a key player in the future of precision medicine, blending AI and data analytics to reshape healthcare delivery. 17, 2024-- Tempus AI, Inc. Jun 14, 2024 · Tempus AI, Inc. As part of the agreement with Avalon, … Continued What does Tempus AI do? Tempus AI is a health technology company founded in 2015. Investors have found the Jul 9, 2024 · Tempus AI Inc. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable … Continued Their comprehensive testing services include genomic sequencing, clinical trial matching, and algorithmic testing. (NASDAQ:TEM) stands against other top AI stocks Feb 5, 2025 · About Tempus AI. Tempus AI is a technology company that focuses on advancing precision medicine by applying artificial intelligence ("AI') in healthcare. 82 per hour for Operations Associate to $20. John Pfeifer, Vice President of Clinical Cardiology at Tempus. Tempus One can identify and enroll patients for trials, create patient timelines, draft prior authorization forms, and explore data for adverse events and symptoms. The forecasts range from a low of 111 What Does Tempus Ai Do jobs available on Indeed. Stock up 98. 52 per hour for Quality Control Associate. Tempus AI Inc (Tempus) is a healthcare technology company that collects and analyzes molecular, clinical and genomic data through the utilization of artificial intelligence technology. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. Dec 11, 2024 · (Tempus owns 20% of Pathos, and they share data and a C-suite executive. Discover how Tempus AI is revolutionizing medical decisions with AI, covering its products, partnerships, and the journey to becoming a healthcare leader. 4 days ago · The Nancy Pelosi tracker on X cited Pelosi's SEC disclosures, which show she bought 50 call options of Tempus AI (NASDAQ TEM) stock options at a strike price of $20. Tempus What does Tempus AI do? Tempus AI is a health technology company founded in 2015. Dec 19, 2024 · Tempus, a technology company focused on advancing precision medicine through the practical application of artificial intelligence in healthcare, relies heavily on data collection and analysis to achieve its goals. 16 I’d say it’s a short, but given the AI hype it’s difficult to know over what timeframe the short will work; one could easily end up losing Feb 19, 2025 · Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $20. From optimizing clinical trials to enhancing research efficiency, generative AI enables us to unlock new opportunities and insights in healthcare. Tempus AI’s platform is primarily used by healthcare providers and researchers. TEM Description — Tempus AI Inc. Feb 20, 2025 · Tempus AI (NASDAQ: TEM) e Genialis hanno annunciato una collaborazione pluriennale per sviluppare nuovi algoritmi basati su RNA per il trattamento del cancro. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM. Co. Since that addition, the stock has seen a Feb 13, 2025 · Tempus AI, Inc. 0 in the Jan 21, 2025 · Tempus AI, Inc. The company has built the world’s largest library of clinical and molecular data and is now valued at more than $8 billion dollars. This AI-based algorithm helps identify patients who may be at increased risk of atrial fibrillation/flutter (AF), marking the first FDA clearance for an AF indication in the "cardiovascular What does Tempus AI do? Tempus AI is a health technology company founded in 2015. Jan 21, 2025 · Tempus AI, Inc. 82 m in annual revenue in FY 2023. Nov 8, 2024 · Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. 44%) and underperforming the diagnostics & research stocks industry (28. 4 days ago · What time does Tempus AI, Inc. Clearly, there is a belief that large real world databases can be powerful tools to aid drug discovery and candidate selection for clinical trials. is a technology company specializing in the collection and analysis of clinical and molecular data to improve patient outcomes. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. 88%, reaching $73. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230. The purchases totaled Tempus AI, Inc. The company is particularly known for its advancements in precision medicine, utilizing artificial intelligence to create How much does Tempus AI - Management in the United States pay? The average Tempus AI salary ranges from approximately $59,000 per year for Quality Coordinator to $268,000 per year for Vice President of Business Development. AI is already helping to detect breast cancer years before it’s first seen in traditional imaging. As a leading provider of AI-powered solutions, Tempus AI has been instrumental in helping organizations streamline their operations, increase Nov 15, 2024 · The panel featured Dr. Jan 4, 2025 · Tempus AI is a platform that uses AI and machine learning algorithms to analyze large amounts of genomic and clinical data to identify patterns and relationships that can help improve patient outcomes, reduce healthcare costs, and accelerate medical research. Tempus AI, Inc. The Investor Relations website contains information about Tempus AI's business for stockholders, potential investors, and financial analysts. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, representing approximately 30% growth year-over Jan 7, 2025 · Tempus AI delivered adjusted EBITDA of -$21. They claim to: "unlock the power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Feb 11, 2025 · How much does Tempus AI - Information Design & Documentation in Chicago pay? The average Tempus AI salary ranges from approximately $47,834 per year for Junior Data Analyst to $110,000 per year for Senior Data Analyst. (NASDAQ:TEM) has provided preliminary Q4 2024 results that will provide for a 30% year-over-year growth rate at the top line. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. Feb 11, 2025 · How much does Tempus AI in the United States pay? The average Tempus AI salary ranges from approximately $46,964 per year for Clinical Associate to $168,000 per year for Process Engineer. 3, 2025-- Tempus AI, Inc. Feb 24, 2025 · Tempus AI (TEM) reports Q4 earnings Monday, expected loss of 20 cents/share, $203. Jan 14, 2025 · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities Jan 20, 2020 · Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, unveils its AI-enabled laboratory test (smart test) platform. ) Masayoshi Son, chairman and CEO of SoftBank (center) shakes hands with Tempus AI COO Ryan Fukushima (left) while Lefkofsky joins on screen. In this article, we are going to take a look at where Tempus AI, Inc. Oct 24, 2024 · Tempus AI, Inc. Tempus is an AI-enabled precision medicine platform that leverages data and artificial intelligence to accelerate discovery, predict treatment effectiveness, identify clinical trials, and diagnose diseases earlier. With the Ambry deal expected to close in Q1 2025, How much does an Operations Associate make at Tempus AI in the United States? Average Tempus AI Operations Associate yearly pay in the United States is approximately $60,823, which is 10% above the national average. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Jan 14, 2025 · Tempus AI (NASDAQ: TEM) has unveiled new generative AI capabilities for its Tempus One platform, enhancing its ability to analyze unstructured healthcare data. Tempus AI Inc is a technology company. (TEM) stock quote, history, news and other vital information to help you with your stock trading and investing. As a member of Congress, Nancy Pelosi is required to submit filings that disclose her and her husband's stock sales and purchases. Understand its growth, tech innovations, and future in healthcare. Tempus reports a fourth-quarter adjusted loss of 18 cents per share, beating analyst estimates Work wellbeing score is 67 out of 100. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U. Founded by Eric Lefkofsky in the year 2015. " Oct 29, 2024 · Tempus AI, Inc (NASDAQ:TEM), a 9-year-old mid-cap healthcare technology company, that only recently donned its listed entity cape, has done relatively well for its stakeholders; Other AI Healthcare Applications. The company is headquartered in Chicago, Illinois. Please note that any opinions, estimates or forecasts regarding Tempus AI's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tempus AI or its management. See insights on Tempus AI including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Average Tempus AI hourly pay ranges from approximately $18. Feb 26, 2025 · Skyrocketing 108% since the start of 2025, Tempus AI (TEM 0. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using Tempus | SoftBank Group Corp. Beginning today, xT CDx is now available for all ordering clinicians nationwide. Tempus AI does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or Feb 15, 2025 · Tempus AI Inc is a technology company. Strong revenue growth, particularly in data Jan 21, 2025 · Tempus Ai stock surges on latest Pelosi disclosure. The average target is $63. 8 million in the third quarter, which was a $14. Jan 15, 2025 · Tempus AI, Inc. Jan 8, 2025 · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for How does Tempus AI stock forecast compare to its benchmarks? Tempus AI's stock forecast shows a 26. 0 to $120. TEM, an artificial intelligence-powered precision medicine solutions provider, which was listed on exchanges in June 2024 has seen major funds investing in the company during the Mar 4, 2025 · The Tempus AI Trade. This award recognizes businesses that go out of their way to provide employees with the support — both financial and non-financial — they need to thrive. Candidates applying for Computational Biologist had the quickest hiring process (on average 1 day), whereas Data Specialist roles had the slowest hiring process (on Dec 17, 2024 · Tempus AI, Inc. Tempus AI posted $200 million in Q4 revenue, up 35% year-over-year. (TEM) reported its fourth-quarter financial results after the market close on Monday, with a mixed bag of outcomes that sent shares lower in after-hours trading. 4 million—a 30% year-on-year increase $381. Find the latest Tempus AI, Inc. 00 and a low estimate of $54. has a VGM Score of C (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style . The AI-focused precision medicine and patient care company missed revenue estimates but beat earnings per share (EPS) expectations, while also providing strong guidance Feb 19, 2025 · Tempus AI Inc. David Ouyang, Cardiologist and Assistant Professor at Cedars-Sinai and UCLA, and Dr. The company's AI platform processes this data to generate actionable insights that can be accessed through products like Tempus One (an AI clinical assistant), Tempus Hub (a provider portal), and various other specialized solutions. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to Feb 3, 2025 · CHICAGO--(BUSINESS WIRE)--Feb. Jun 26, 2024 · Tempus AI, Inc. 7 Jan 13, 2025 · Tempus AI, Inc. In addition, AI is helping to identify patients at risk for cardiovascular disease. "The ability to deploy AI in precision medicine at scale has only recently become possible," the company said in an SEC filing. She bought 50 of the January 2026 $20 call options on January 14 th. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult Oct 29, 2024 · Tempus AI has 1 employees across 10 locations and $531. Jan 27, 2025 · Tempus AI began trading publicly on June 14, 2024. 8 3 days ago · What do analysts say about Tempus AI, Inc. Tempus is also working on applying its AI platform across a range of other healthcare initiatives, from cardiology to mental health. TEM stock was listed on June 14, 2024 Tempus is a cutting-edge healthcare technology company that leverages artificial intelligence to transform precision medicine. Nov 7, 2024 · Tempus AI, Inc. ONCOLOGY /// GENOMIC PROFILING One platform for precision oncology. (TEM. The collaboration, which is expected to span across several disease conditions over time, will start with the Feb 28, 2025 · Tempus - AI-based precision medicine solutions for oncology. com. Tempus has 37 competitors. 94 per hour for Clinical Laboratory Scientist to $31. The conversation centered on the potential of AI to close diagnostic gaps and improve patient outcomes, particularly in the context … Continued Jan 16, 2025 · What Does Tempus AI Do? Tempus AI is a cutting-edge artificial intelligence (AI) platform that has revolutionized the way businesses approach time management, scheduling, and workflow optimization. 8, 2025-- Tempus AI, Inc. 17, accompanied by a high estimate of $74. Should You Invest $1,000 in Tempus AI Right Now? Before you consider Tempus AI, you'll want to hear this. As a leading provider of AI-powered solutions, Tempus AI has been instrumental in helping organizations streamline their operations, increase Jan 27, 2025 · Tempus AI (NASDAQ: TEM), a healthcare technology company, saw its stock surge 45% in a week after the company announced the launch of its AI app – Olivia. Current RSI values indicate that the stock is may be overbought. Nov 12, 2024 · Tempus AI is a very competent investment opportunity for long-term investors in the growing field of precision medicine using artificial intelligence. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the Institute for Follicular Lymphoma Innovation. " Tempus is a company that uses AI to accelerate the discovery, prediction, and diagnosis of diseases, especially cancer. AI & ML in action: Unlocking RWD with GenAI through Tempus LensTuesday, March 25, 2025 11 AM PT / 1 PM CT / 2 PM ET Feb 11, 2025 · Tempus AI's Current Market Status With a trading volume of 15,942,711, the price of TEM is up by 6. The … Continued Jun 13, 2023 · On the radiology side, radio-omics is an emerging field. 4 million year-over-year improvement and also a significant improvement quarter over quarter. Next Reviews from Tempus AI employees about Pay & Benefits. Feb 25, 2025 · Indeed, Tempus AI noted in its earnings call that growing long-term at 25% would be a ''perfectly solid growth rate'', driven not just by its Genomics business but also by its Data and AI Dec 31, 2024 · CHICAGO --(BUSINESS WIRE)--Jan. 31 per hour for Order Processor. was founded to develop its Tempus Platform, which gathers data from various silos and combines it with AI-driven capabilities to help physicians and Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. 05B over 8 rounds from 11 investors. Analysts see 13. The company’s quarterly earnings will be released the same day. evwdfjd sxsgq kzpks ralfl kiqfh tltat bikbr eigtap bpk dpu zbjjssg tiq ftgdmig nmsculf vtzeb